Stock Quote
Alexion Pharmaceuticals, Inc. (ALXN.W) (NASD ADF)
$43.71
20 Nov 2009
-0.97%
$44.14
$43.71
100
$43.71
$43.71
$48.93
$28.16
0.60
600,432
ALXN.W
More News
| Press Releases
| Key Developments
| Name | Current Position | Compensation |
|---|---|---|
| Link, Max | Chairman of the Board | -- |
| Bell, Leonard | Chief Executive Officer, Secretary, Treasurer, Director | 3,939,350 |
| Sinha, Vikas | Chief Financial Officer, Senior Vice President | 2,072,930 |
Profile
Alexion Pharmaceuticals, Inc. (Alexion) is a biopharmaceutical company engaged in the discovery, development and delivery of biologic therapeutic products for the treatment disease, including hematologic and neurologic diseases, cancer and autoimmune disorders. The Company has one marketed product,... Full Description
Company Address
Alexion Pharmaceuticals, Inc.
352 Knotter Drive
Cheshire CT 06410
P: +1203.2722596
F: +1203.2718198
352 Knotter Drive
Cheshire CT 06410
P: +1203.2722596
F: +1203.2718198
Analyst Research
Performance of Key Competitors
| Company | Price | Change |
|---|---|---|
| Arana Therapeutics Limited | $1.39 | 0.00 |
| XOMA Limited | $0.72 | -0.01 |
| Novo Nordisk A/S | kr.330.00 | -1.00 |
| ALXN.W | Industry | |
|---|---|---|
| P/E(TTM) | 52.87 | 12.80 |
| P/S(TTM) | 10.95 | 29.90 |
| ROI(TTM) | 18.05 | 2.35 |
| ROE(TTM) | 24.42 | 3.59 |
| Consensus Recommendation | Outperform |
|---|---|
| EPS Est. (Current Period) | 0.28 |
| EPS Est. (Current Year) | 0.90 |
| Total Revenue | $102.63M |
| Net Income | $26.73M |
| EPS | $0.29 |
